Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Announces New Compelling Results On Ozoralizumab (ATN-103) In Rheumatoid Arthritis
Ablynx NV announced that its anti-TNFa Nanobody, ozoralizumab (ATN-103), for the treatment of inflammatory diseases, showed safety and efficacy results in the 48-week open-label extension (OLE) study of the worldwide and Japanese Phase II trials in the treatment of patients with Rheumatoid Arthritis (RA) who have an insufficient response to methotrexate alone.
Latest Developments for Ablynx NV
- Ablynx NV to Present Pre-Clinical Proof-of-Concept Data on ALX-0761 at ACR
- Ablynx NV Elects New Chairman Of Board
- Ablynx NV Updates on Phase II Part of Combined Phase I/II Study of Anti-IL-6R Nanobody, ALX-0061 Results
- Ablynx NV Updates on Results of Phase I/II Study with Anti-Il-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients
Latest Key Developments in Biotechnology
- TRANS GENIC INC expects extraordinary profit
- BioSpecifics Technologies Corp announces board authorization of up to $2 million stock repurchase program
- Insys Therapeutics Inc receives subpoena from Office of Inspector General
- Synta Pharmaceuticals Corp announces positive interim results from the ENCHANT-1 Trial
- Share this
- Digg this